Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
October 09, 2025 02:00 ET | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…
NEXTCHEM WILL PROVIDE THE FUEL CELL MODULES, WHILE SIEMENS ENERGY WILL PROVIDE ON BOARD SYSTEM INTEGRATION AND ENERGY MANAGEMENT SYSTEM…
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for cancer care in Eastern India, doctors at Apollo…
Leiden, The Netherlands – September 15, 2025 – ProteoNic, a leader in premium vector technology for biologics and cell and…
September 09, 2025 13:19 ET | Source: Booking Health Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a…
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,…
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules.WuXia293Stable platform maintains…
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for…